Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05318014
Other study ID # CF19237B
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2019
Est. completion date December 31, 2021

Study information

Verified date March 2022
Source Taichung Veterans General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective randomized contorl study.Comparing clinical outcome between chronic kidney disease who were prescribed 6% low-protein nutrition supplement along with dietatian regular nutrition education and those without oral nutrition supplement.


Description:

Past studies have shown that supplementation with low-protein nutritional formulas helps to increase compliance with low-protein diet control, but few studies have explored low-protein nutritional formulas supplementing the calories chronic kidney disease patient need, and nutritional supplements rich in ω-3 fatty acids, vitamin D and essential amino acid having effect in chronic renal function and changes in muscle mass, strength, and mobility. The propose of this study that low protein supplement may help maintain renal function or delay deterioration of renal function, or may reduce the risk of malnutrition and further improve muscle strength and mobility or quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date December 31, 2021
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Subject is >65years of age. 2. Subject has been diagnosed with Chronic Kidney Disease (CKD) and is classified as being between Stages 3 to 5. Exclusion Criteria: 1. The physician determines that the clinical condition is unstable. 2. Lower limb injury or severe edema. 3. food allergies to milk, or fish 4. There is a heart rhythm in the body and a prosthetic device. 5. Those who are unable to complete the questionnaire due to severe cognitive impairment as determined by the physician.

Study Design


Intervention

Dietary Supplement:
Intervention group
dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
Other:
Regular nutrition education
dietitian regular nutrition educataion which was following a low protein diet

Locations

Country Name City State
Taiwan Taichung Verterans General Hospital Taichung Taichung

Sponsors (1)

Lead Sponsor Collaborator
Taichung Veterans General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of muscle strength Hand grip strength Baseline to 12 weeks and 24 weeks
Primary Change of Gait speed Gait speed measurement Baseline to 12 weeks and 24 weeks
Primary Change of 5-meter distance walk 5-meter distance walk measurement Baseline to 12 weeks and 24 weeks
Primary Change of nutrition status Mini Nutritional Assessment Short-Form score Baseline to 12 weeks and 24 weeks
Primary Change of body composition Using bioelectrical impedance analysis(BIA, Tanita MC-780, Japan) Baseline to 12 weeks and 24 weeks
Primary Change of total energy intake 24-hour dietary record measurement Baseline to 12 weeks and 24 weeks
Primary Change of protein intake 24-hour dietary record measurement Baseline to 12 weeks and 24 weeks
Primary Change of carbohydrate intake 24-hour dietary record measurement Baseline to 12 weeks and 24 weeks
Primary Change of fat intake 24-hour dietary record measurement Baseline to 12 weeks and 24 weeks
Primary Change of micronutrients intake 24-hour dietary record measurement Baseline to 12 weeks and 24 weeks
Secondary Change of serum creatinine renal function monitoring Baseline to 12 weeks and 24 weeks
Secondary Change of blood urea nitrogen renal function monitoring Baseline to 12 weeks and 24 weeks
Secondary Change of estimated glomerular filtration rate renal function monitoring Baseline to 12 weeks and 24 weeks
Secondary Change of daily protein intake. 24-hour urine estimated protein intake with Maroni formula Baseline to 12 weeks and 24 weeks
Secondary Change of albumin Change of albumin in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of sodium electrolyte measurement in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of potassium electrolyte measurement in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of calcium electrolyte measurement in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of phosphorus electrolyte measurement in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of magnesium electrolyte measurement in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of Hemoglobin A1c monitoring and diagnosis diabetes Baseline to 12 weeks and 24 weeks
Secondary Change of blood sugar Blood sugar testing Baseline to 12 weeks and 24 weeks
Secondary Change of CRP Change of CRP in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of red blood cell Routine Blood Tests in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of White blood cell Routine Blood Tests in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of hemoglobin Routine Blood Tests in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of hematocrit Routine Blood Tests in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of liver function Change of ALT and AST in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of cholesterol Change in lipid analysis in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of triglyceride Change in lipid analysis in the blood Baseline to 12 weeks and 24 weeks
Secondary Change of LDL-cholesterol Change in lipid analysis in the blood Baseline to 12 weeks and 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4
Withdrawn NCT02207751 - Improving Outcomes in Peritoneal Dialysis N/A